Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Astellas Innovation Debate

- PMLiVE

NICE U-turn on Crystiva for rare bone disease

Watchdog to back the drug to treat young people with XLH

- PMLiVE

MHRA cut out of regulatory work as Brexit looms

This year the regulatory body was only awarded two contracts to serve as the lead assessor on NDAs

- PMLiVE

Social care crisis looms as demand to double by 2035

England unprepared after years of delaying hard decisions

- PMLiVE

UK says firms should stockpile drugs in case of no-deal Brexit

Government also confirms the MHRA will handle UK marketing applications for new medicines

- PMLiVE

AI company Sensyne raises £60m in IPO

University of Oxford-developed tech powers health-focused company

- PMLiVE

Confidence in UK’s post-Brexit healthcare sector on the wane

Only 37% of healthcare workers agree that the UK would be an attractive destination after EU departure

- PMLiVE

Human Cell Atlas gets new UK funding

The project will allow researchers to define characteristics of single cell types

- PMLiVE

Bringing the NHS into the 21st century

As the NHS celebrates its 70th birthday and a £20bn “birthday gift” from the UK government, we find out how one company is delivering what the National Health Service really...

Blue Latitude Health

- PMLiVE

Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?

The next generation of relationship holders will offer highly personalised services

- PMLiVE

Happy 70th birthday NHS: the next 70 need to be very different

The UK’s NHS is loved by the British public, while social care is under appreciated and underfunded. The new health secretary is being urged to remedy this to create a...

- PMLiVE

Love Island ads fuel body image problems, warn health leaders

Calls for watchdog to regulate cosmetic surgery adverts

- PMLiVE

NHS England to Vertex: come clean on Orkambi offer

Vertex has offered Orkambi at an almost 90% discount to the NHS, according to BioCentury

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links